Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Rydell-Törmänen, G. Westergren-Thorsson (Lund, Sweden). Bleomycin-induced remodeling – Inflammation and fibrosis are developing in parallel during initiation. Eur Respir J 2011; 38: Suppl. 55, 674

Member's Comments

No comment yet.

Related content which might interest you: Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Resveratrol regulates ECM remodeling in lung fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Clinical analysis of chronic hypersensitivity pneunonitis – Comparison with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease Year: 2010 Airway-centered interstitial fibrosis – Two case reports Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Severe lung inflammation is a feature of IPF Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Epithelial mesenchymal transition in fibroblastic foci of different fibrosing lung diseases: Repair or remodeling? Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 Late Breaking Abstract - PRRX1 inhibition decreases fibrosis in the bleomycin-induced lung fibrosis model in mice Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Collagen V activation and matrix extracellular remodeling mediated pulmonary fibrosis in experimental models of bleomycin and 3-5-di-tert-4-hidroxitoluene Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Regulation of WISP1 by profibrotic cytokines in pulmonary fibrosis Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells Year: 2014 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Evolution of biomechanical changes in a murine model of bleomycin-induced lung fibrosis: inflammation versus fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 396s Year: 2006 The pathogenesis of pulmonary fibrosis: a moving target Source: Eur Respir J 2013; 41: 1207-1218 Year: 2013 Aerobic exercise reduces lung inflammation and fibrosis mediated by serotoninergic/Akt signaling in a model of pulmonary fibrosis Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy Source: International Congress 2016 – IPF pathogenesis Year: 2016 Targeting the IL-1β – IL-17A inflammatory axis for the treatment of viral-induced exacerbations of COPD Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012 The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Role of Wnt-1, Wnt-3 and MMP-7 in fibrotic response in extrinsic allergic alveolitis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015